Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Accumulated Expenses (2020 - 2025)

SAB Biotherapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 20.76% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 20.76%, while the annual FY2025 figure was $5.0 million, 20.76% up from the prior year.
  • Accumulated Expenses reached $5.0 million in Q4 2025 per SABSW's latest filing, up from $3.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.0 million in Q4 2025 to a low of $21542.0 in Q2 2025.
  • Average Accumulated Expenses over 5 years is $1.2 million, with a median of $298240.0 recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 851.43% in 2023 against a maximum downside of 91.88% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $674858.0 in 2021, then tumbled by 47.04% to $357390.0 in 2022, then skyrocketed by 851.43% to $3.4 million in 2023, then increased by 22.65% to $4.2 million in 2024, then grew by 20.76% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Accumulated Expenses are $5.0 million (Q4 2025), $3.7 million (Q3 2025), and $21542.0 (Q2 2025).